Iron overload in MDS-pathophysiology, diagnosis, and complications

Annals of Hematology

Volumn 90, Issue 1, 2011, Pages 1-10

  Gattermann, Norbert ^b   Rachmilewitz, Eliezer A ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Iron chelation; Iron overload; Labile plasma iron; Myelodysplastic syndromes; Non transferrin bound iron; Oxidative stress

Indexed keywords

CD34 ANTIGEN; DEFERASIROX; DEFERIPRONE; FERRITIN; GLUTATHIONE; HEPCIDIN; IRON; MITOCHONDRIAL DNA; PLASMA CELLULAR IRON; PLASMA LABILE IRON; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; BLOOD TRANSFUSION; BONE MARROW CELL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; DNA DAMAGE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; EVENING DOSAGE; FERRITIN BLOOD LEVEL; GENOMIC INSTABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON ABSORPTION; IRON BINDING CAPACITY; IRON CHELATION; IRON OVERLOAD; IRON RELEASE; IRON TRANSPORT; LEUKEMIC TRANSFORMATION; LIFE EXPECTANCY; LIPID PEROXIDATION; LIVER FAILURE; MACROPHAGE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; SIDE EFFECT; SURVIVAL TIME; THALASSEMIA; THROMBOCYTE; TRANSFUSION DEPENDENCY; TRANSFUSIONAL IRON OVERLOAD;

ANIMALS; BLOOD TRANSFUSION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; LIFE EXPECTANCY; MODELS, BIOLOGICAL; MYELODYSPLASTIC SYNDROMES; OXIDATIVE STRESS;

EID: 78651287827     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1091-1     Document Type: Review

References (76)

1. U Germing C Strupp A Kuendgen S Isa S Knipp B Hildebrandt A Giagounidis C Aul N Gattermann R Haas 2006 Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes Haematologica 91 1596 1604 17145595
2. GF Sanz MA Sanz T Vallespi MC Canizo M Torrabadella S Garcia D Irriguible JF San Miguel 1989 Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients Blood 74 395 408 1:STN:280:DyaL1MzitleltQ%3D%3D 2752119
3. T Tanno NV Bhanu PA Oneal SH Goh P Staker YT Lee JW Moroney CH Reed NL Luban RH Wang TE Eling R Childs T Ganz SF Leitman S Fucharoen JL Miller 2007 High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nat Med 13 1096 1101 1:CAS:528:DC%2BD2sXhtVSgtrvK 10.1038/nm1629 17721544 (Pubitemid 47517510)
4. T Tanno P Porayette O Sripichai SJ Noh C Byrnes A Bhupatiraju YT Lee JB Goodnough O Harandi T Ganz RF Paulson JL Miller 2009 Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells of the iron regulatory protein hepcidin Blood 114 181 186 1:CAS:528:DC%2BD1MXhtVOkurvE 10.1182/blood-2008-12-195503 19414861
5. A Winder R Lefkowitz H Ghoti M Leiba T Ganz E Nemeth EA Rachmilewitz 2008 Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis Br J Haematol 142 669 671 10.1111/j.1365-2141.2008.07225.x 18498424 (Pubitemid 352020208)
6. N Gattermann 2005 Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators Hematol Oncol Clin North Am 19 suppl 1 13 17
7. T Ganz 2003 Hepcidin, a key regulator of iron metabolism and mediator of anemia and inflammation Blood 102 783 788 1:CAS:528:DC%2BD3sXlvFCms7g%3D 10.1182/blood-2003-03-0672 12663437 (Pubitemid 36917762)
8. E Nemeth MS Tuttle J Powelson MB Vaughn A Donovan DM Ward T Ganz J Kaplan 2004 Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization Science 306 2090 2093 1:CAS:528:DC%2BD2cXhtVOjsL3K 10.1126/science.1104742 15514116 (Pubitemid 40007660)
9. C Hershko G Graham GW Bates E Rachmilewitz 1978 Non-specific serum iron in thalassemia: an abnormal serum iron fraction of potential toxicity Br J Haematol 40 255 263 1:CAS:528:DyaE1cXmtFeisrg%3D 10.1111/j.1365-2141.1978. tb03662.x 708645
10. ZI Cabantchik W Breuer G Zanninelli P Cianciulli 2005 LPI-labile plasma iron in iron overload Best Pract Res Clin Haematol 18 277 287 1:CAS:528:DC%2BD2MXhvVSmtb0%3D 10.1016/j.beha.2004.10.003 15737890 (Pubitemid 40298370)
11. DB Kell 2009 Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases BMC Med Genet 2 2 10.1186/1755-8794-2-2
12. L Malcovati MG Della Porta C Pascutto R Invernizzi M Boni E Travaglino F Passamonti L Arcaini M Maffioli P Bernasconi M Lazzarino M Cazzola 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594 7603 10.1200/JCO.2005.01.7038 16186598 (Pubitemid 46291823)
13. G Sanz B Nomdedeu E Such T Bernal M Belkaid MT Ardanaz V Marco C Pedro F Ramos C del Canizo E Luno F Cobo F Carbonell V Gomez JA Munoz ML Amigo A Bailen B Bonanad M Tormo R Andreu B Arrizabalaga MJ Arilla J Bueno MJ Requena J Bargay J Sanchez L Senent L Arenillas R de Paz B Xicoy R Duarte J Cervera 2008 Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome Blood 112 640 10.1182/blood-2008-05-159632 ASH (Annual Meeting Abstracts)
14. L Malcovati U Germing A Kuendgen MG Della Porta C Pascutto R Invernizzi A Giagounidis B Hildebrandt P Bernasconi S Knipp C Strupp M Lazzarino C Aul M Cazzola 2007 Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 3503 3510 10.1200/JCO.2006.08.5696 17687155 (Pubitemid 47315575)
15. CE Chee DP Steensma W Wu CA Hanson A Tefferi 2008 Neither serum ferritin nor number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts Am J Hematol 83 611 613 1:CAS:528: DC%2BD1cXhtVGls7jN 10.1002/ajh.21192 18442062
16. AA di Tucci G Matta S Deplano A Gabbas C Depau D Derudas G Caocci A Agus E Angelucci 2008 Myocardial iron overload assessment by T2*magnetic resonance imaging in adult transfusion dependent patients with acquired anemias Haematologia 93 1385 1388 10.3324/haematol.12759
17. JM Bennett 2008 MDS Foundation's Working Group on transfusional iron overload. Consensus statement on iron overload in myelodysplastic syndromes Am J Hematol 83 858 861 10.1002/ajh.21269 18767130
18. L Malcovati MG Della Porta M Cazzola 2006 Predicting survival and leukemic evolution in patients with myelodysplastic syndrome Haematologica 91 1588 1590 17145593
19. F Rassool TJ Gaymes N Omidvar N Brady S Beurleut M Pla M Reboul N Lea C Chomienne NSB Thomas GJ Mufti RA Padua 2007 Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 67 8762 8771 1:CAS:528:DC%2BD2sXhtVCit7vE 10.1158/0008-5472.CAN-06-4807 17875717 (Pubitemid 47437452)
20. A Sallmyr J Fan FV Rassoul 2008 Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair Cancer Lett 207 1 9 10.1016/j.canlet.2008.03.036
21. V Pullarkat 2009 Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114 5251 5255 1:CAS:528: DC%2BC3cXislWktw%3D%3D 10.1182/blood-2009-07-234062 19710499
22. Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N (2009) Matched-pair analysis of 186 MDS patients receiving long-term iron chelation therapy or transfusion therapy only. Blood: ASH (Annual Meeting Abstracts), #1747
23. C Peddie CR Wolf LI McLellan AR Collins D Bowen 1997 Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-α concentration Br J Haematol 99 625 631 1:CAS:528:DyaK2sXnvF2ltrk%3D 10.1046/j.1365-2141.1997.4373247.x 9401076
24. D Bowen L Wang M Frew R Kerr M Groves 2003 Antioxidant enzyme expression in myelodysplastic and acute myeloid leukemia bone marrow: further evidence of a pathogenetic role for oxidative stress? Haematologica 88 1070 1072 1:CAS:528:DC%2BD3sXovVarsrg%3D 12969817
25. B Novotna Y Bagryantseva M Siskova R Neuwirtova 2009 Oxidative damage in bone marrow cells of patients with low-risk myelodysplastic syndrome Leuk Res 33 340 343 1:CAS:528:DC%2BD1cXhsVChtrjK 18687469
26. AM Jankowska LP Gondek H Szpurka ZP Nearman RV Tiu JP Maciejewski 2008 Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome Leukemia 22 551 558 1:CAS:528:DC%2BD1cXjt1Ggu7s%3D 10.1038/sj.leu. 2405055 18059482 (Pubitemid 351386725)
27. H Ghoti J Amer A Winder E Rachmilewitz E Fibach 2007 Oxidative stress in red blood cells, platelets, and polymorphonuclear leukocytes from patients with myelodysplastic syndromes Eur J Haematol 79 463 467 10.1111/j.1600-0609.2007. 00972.x 17976187 (Pubitemid 350126678)
28. A Cortelezzi C Cattaneo B Sarina S Cristiani M Pomati I Silvestris M Motta A Ibatici G Gornati AD Volpe AT Maiolo 2000 Efficacy of N-acetylcysteine and all-trans retinoid acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes Leuk Res 24 129 137 1:CAS:528:DyaK1MXnvFeit7o%3D 10.1016/S0145-2126(99)00165-4 10654448
29. A Cortelezzi C Cattaneo S Cristiani L Duca B Sarina GL Deliliers G Fiorelli MD Cappellini 2000 Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J 1 153 158 1:STN:280:DC%2BD387oslCkuw%3D%3D 10.1038/sj.thj.6200028 11920184
30. H Ghoti E Fibach D Merkel G Perez-Avraham S Grisariu E Rachmilewitz 2010 Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes Haematologica 95 1433 1434 10.3324/haematol.2010.024992 20421274
31. Gattermann N (2009) The role of mitochondria in MDS. In: Steensma DP (ed) Myelodysplastic syndromes: pathobiology and clinical management. Informa Healthcare Ltd, New York, pp 127-151
32. X Gao JL Campian M Qian XF Sun JW Eaton 2009 Mitochondrial DNA damage in iron overload J Biol Chem 284 4767 4775 1:CAS:528:DC%2BD1MXhvVSgtbg%3D 10.1074/jbc.M806235200 19095657
33. SO Choi YS Cho HL Kim JW Park 2007 ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBP alpha and STAT-3 Biochem Biophys Res Comm 356 312 317 1:CAS:528:DC%2BD2sXjt1Snur4%3D 10.1016/j.bbrc.2007.02.137 17349976 (Pubitemid 46413166)
34. Ghoti H, Fibach E, Merkel D, Amer J, Nagler A, Levi I, Grisarium S, Naparstek E, Ackerstein A, Olbina G, Westerman M, Ganz T, Rachmilewitz E (2009) Decrease in intra- and extra-cellular free iron species and oxidative stress parameters and increase in serum and urinary hepcidin during treatment with Deferasirox in iron-loaded patients with MDS. Hematologica 2009; 94[suppl. 2]: 322 abs. 0797
35. M Takatoku T Uchiyama S Okamoto Y Kanakura K Sawada M Tomonaga S Nakao T Nakahata M Harada T Murate K Ozawa 2007 Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload in morbidity/mortality Eur J Haematol 78 487 494 1:CAS:528:DC%2BD2sXotV2gsbc%3D 10.1111/j.1600-0609.2007.00842.x 17391310 (Pubitemid 46753591)
36. SL Goldberg E Chen M Corral A Guo N Mody-Patel AL Pecora M Laouri 2010 Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries J Clin Oncol 28 2847 2852 10.1200/JCO.2009.25.2395 20421543
37. M Jaeger C Aul D Sohngen U Germing W Schneider 1992 Iron overload in polytransfused patients with MDS: use of L1 for oral iron chelation Drugs Today 28 Suppl A 143 147
38. AI Schafer RG Cheron R Dluhy B Cooper RE Gleason JS Soeldner HF Bunn 1981 Clinical consequences of acquired transfusional iron overload in adults N Engl J Med 304 319 324 1:STN:280:DyaL3M%2FnsV2itw%3D%3D 10.1056/NEJM198102053040603 6777701
39. EN Oliva BD Dimitrov F Benedetto A D'Angelo F Nobile 2005 Hemoglobin level threshold for cardiac remodelling and quality of life in myelodysplastic syndrome Leuk Res 29 1217 1219 1:CAS:528:DC%2BD2MXos1ahsb0%3D 10.1016/j.leukres.2005.03.004 16111537 (Pubitemid 41169239)
40. J Chacko DJ Pennell MA Tanner TJ Hamblin B Wonke T Levy PW Thomas SB Killick 2007 Myocardial iron loading by magnetic resonance imaging T2*in good prognostic myelodysplastic syndrome patients on long-term blood transfusions Br J Haematol 138 587 593 1:CAS:528:DC%2BD2sXhtVKgsr7P 10.1111/j.1365-2141.2007.06695.x 17610536 (Pubitemid 47206717)
41. Glanville J et al (2006) MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anemias. Blood (ASH Abstract 1553)
42. E Konen H Ghoti O Goitein A Winder T Kushnir Y Eshet E Rachmilewitz 2007 No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2*technique Am J Hematol 82 1013 1016 10.1002/ajh.20980 17654681 (Pubitemid 350004394)
43. LM Buja WC Roberts 1971 Iron in the heart. Etiology and clinical significance Am J Med 51 209 221 1:STN:280:DyaE38%2Fgs1SisQ%3D%3D 10.1016/0002-9343(71)90240-3 5095527
44. JC Wood M Otto-Duessel M Aguilar H Nick MD Nelson TD Coates H Pollack R Moats 2005 Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of cardiomyopathy Circulation 112 535 543 1:CAS:528:DC%2BD2MXmt1yht7o%3D 10.1161/CIRCULATIONAHA.104.504415 16027257 (Pubitemid 41060794)
45. ML Bassett JW Halliday LW Powell 1986 Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis Hepatology 6 24 29 1:STN:280:DyaL287gvF2nsA%3D%3D 10.1002/hep.1840060106 3943787
46. EP Alessandrino MG Della Porta A Bacigalupo L Malcovati E Angelucci MT Van Lint 2010 Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study Haematologica 95 476 484 1:CAS:528:DC%2BC3cXht12msLrK 10.3324/haematol.2009.011429 19903678
47. JC Wood R Origa A Agus G Matta T Coates R Galanello 2008 Onset of cardiac iron loading in pediatric patients with thalassemia major Haematologica 93 917 920 10.3324/haematol.12513 18413890 (Pubitemid 351821730)
48. A Piga F Longo L Duca S Roggero T Vinciguerra R Calabrese C Hershko MD Cappellini 2009 High nontransferrin bound iron levels and heart disease in thalassemia major Am J Hematol 84 29 33 1:CAS:528:DC%2BD1MXhvVGns7k%3D 10.1002/ajh.21317 19006228
49. PD Jensen FT Jensen T Christensen H Eiskjaer U Baandrup JL Nielsen 2003 Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool Blood 101 4632 4639 1:CAS:528:DC%2BD3sXktFKgsrc%3D 10.1182/blood-2002-09-2754 12576333 (Pubitemid 36857840)
50. HA Leitch CS Leger TA Goodman KK Wong DHC Wong KM Ramadan MD Rollins MJ Barnett PF Galbraith LM Vickars 2008 Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy Clin Leuk 2 205 211 1:CAS:528:DC%2BD1cXhtFSltb3K 10.3816/CLK.2008.n.026
51. C Rose S Brechignac D Vassilief L Pascal A Stamatoullas A Guerci D Larbaa F Dreyfus O Beyne-Rauzy MP Chaury L Roy S Cheze P Morel P Fenaux Myélodysplasies) GGFd 2010 Does iron chelation therapy improve survival in regularly transfused lower risk MDs patients? A multicenter study by the GFM Leuk Res 34 864 870 1:CAS:528:DC%2BC3cXmsVSls7k%3D 10.1016/j.leukres.2009.12.004 20129667
52. EP Alessandrino S Amadori G Barosi M Cazzola A Grossi LN Liberato F Locatelli M Marchetti E Morra P Rebulla G Visani S Tura 2002 Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology Haematologia 87 1286 1306
53. B Arrizabalaga C del Canizo AF Remacha, et al. 2008 Guía clínica de quelación del paciente con síndrome mielodisplásico [Clinical guide to chelation therapy for patients with myelodysplastic syndrome (Spanish guidelines)] Haematologica 93 Suppl 1 3 10
54. D Bowen D Culligan S Jowitt S Kelsey G Mufti D Oscier J Parker 2003 Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes Br J Haematol 120 187 200 10.1046/j.1365-2141.2003.03907.x 12542475 (Pubitemid 36194166)
55. N Gattermann JB Porter LF Lopes J Seymour 2005 Consensus statement on iron overload in myelodysplastic syndromes Hematol Oncol Clin North Am 19 suppl 1 18 25
56. National-Comprehensive-Cancer-Network (2010) NCCN clinical practice guidelines in oncology v.1: myelodysplastic syndromes, 2010. Available at http://www.nccn.org/professionals/physician-gls/pdf/mds.pdf
57. T Suzuki M Tomonaga Y Miyazaki S Nakao K Ohyashiki I Matsumura Y Kohgo Y Niitsu S Kojima K Ozawa 2008 Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes Int J Hematol 88 30 35 1:CAS:528:DC%2BD1cXhtVOktLfE 10.1007/s12185-008-0119-y 18581199
58. P Valent O Krieger R Stauder F Wimazal T Nösslinger WR Sperr H Sill P Bettelheim M Pfeilstöcker 2008 Iron overload in myelodysplastic syndromes (MDS)-diagnosis, management, and response criteria: a proposal of the Austrian MDS platform Eur J Clin Investig 38 143 149 1:CAS:528:DC%2BD1cXktVSitbY%3D 10.1111/j.1365-2362.2007.01915.x (Pubitemid 351197091)
59. RA Wells B Leber R Buckstein JH Lipton W Hasegawa K Grewal K Yee HJ Olney L Larratt L Vickars A Tinmouth 2008 Iron overload in myelodysplastic syndromes: a Canadian consensus guideline Leuk Res 32 1338 1353 1:CAS:528: DC%2BD1cXlvF2qtLc%3D 10.1016/j.leukres.2008.02.021 18405971
60. N Gattermann 2008 Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndomes and transfusional iron overload Int J Hematol 88 24 29 10.1007/s12185-008-0118-z 18581200
61. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellström-Lindberg E (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
62. P Greenberg C Cox MM LeBeau P Fenaux P Morel G Sanz M Sanz T Vallespi T Hamblin D Oscier K Ohyashiki K Toyama C Aul J Bennett 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 1:CAS:528:DyaK2sXhvVars70%3D 9058730
63. PD Jensen L Heickendorff B Pedersen K Bendix-Hansen FT Jensen T Christensen AM Boesen J Ellegaard 1996 The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload Br J Haematol 94 288 299 1:STN:280:DyaK28zis1agsw%3D%3D 10.1046/j.1365-2141.1996.d01-1795.x 8759889
64. MJ Kersten R Lange ME Smeets G Vreugdenhil KJ Roozendaal W Lameijer R Goudsmit 1996 Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial Ann Hematol 73 247 252 1:STN:280:DyaK2s7hvFWhsg%3D%3D 10.1007/s002770050236 8959943 (Pubitemid 26401800)
65. List A, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa EC (2009) Two-year analysis of efficacy and safety of deferasirox (Exjade) treatment in myelodysplastic syndrome patients enrolled in the US03 study. Blood: ASH (Annual meeting abstracts), #3829
66. G Metzgeroth D Dinter B Schultheis A Dorn-Beineke K Lutz O Leismann R Hehlmann J Hastka 2009 Deferasirox in MDS patients with transfusion-caused iron overload-a phase-II study Ann Hematol 88 301 310 1:CAS:528:DC%2BD1MXitVOltrw%3D 10.1007/s00277-008-0588-3 18758781
67. J Porter R Galanello G Saglio EJ Neufeld E Vichinsky MD Cappellini N Olivieri A Piga MJ Cunningham D Soulières N Gattermann G Tchernia J Maertens P Giardina J Kwiatkowski G Quarta M Jeng GL Forni M Stadler H Cario L Debusscher M Della Porta M Cazzola P Greenberg G Alimena B Rabault I Gathmann JM Ford D Alberti C Rose 2008 Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anemias to deferasirox (ICL670): a 1-yr prospective study Eur J Haematol 80 168 176 1:CAS:528:DC%2BD1cXivFahtr8%3D 18028431
68. N Gattermann C Finelli M Della Porta P Fenaux A Ganser A Guerci-Bresler M Schmid K Taylor D Vassilief D Habr G Domokos B Roubert C Rose 2010 Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study Leuk Res 34 1143 1150 1:CAS:528:DC%2BC3cXps1Wluro%3D 10.1016/j.leukres.2010.03.009 20451251
69. Greenberg P, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C (2010) Prospective assessment of effects of iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res (in press)
70. AA di Tucci R Murru D Alberti B Rabault S Deplano E Angelucci 2007 Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670) Eur J Haematol 78 540 542 10.1111/j.1600-0609.2007.00840.x 17391307 (Pubitemid 46753589)
71. E Messa D Cilloni F Messa F Arruga A Roetto G Saglio 2008 Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis Acta Haematol 120 70 71 1:CAS:528:DC%2BD1cXhsVGgs7zF 10.1159/000158631 18827475
72. H Glickstein RB El M Shvartsman ZI Cabantchik 2005 Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells Blood 106 3242 3250 1:CAS:528:DC%2BD2MXht1WntrrK 10.1182/blood-2005-02-0460 16020512 (Pubitemid 41565925)
73. H Glickstein RB El G Link W Breuer AM Konijn C Hershko H Nick ZI Cabantchik 2006 Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences Blood 108 3195 3203 1:CAS:528:DC%2BD28XhtFygtrbL 10.1182/blood-2006-05-020867 16835377
74. YF Cheung GCF Chan SY Ha 2008 Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major Br J Haematol 141 728 733 1:CAS:528:DC%2BD1cXotVaqsLg%3D 10.1111/j.1365-2141.2008.07092.x 18318756 (Pubitemid 351667625)
75. Cohen AR, Porter JB (2001) Transfusion and iron chelation therapy in thalassemia and sickle cell anemia. In: MHea S (ed) Disorders of Hemoglobin: genetics, pathophysiology and clinical management. Cambridge, Cambridge University Press, pp 979-1027
76. MJ Farquhar DT Bowen 2003 Oxidative stress and the myelodysplastic syndromes Int J Hematol 77 342 350 1:CAS:528:DC%2BD3sXksFKjtbc%3D 10.1007/BF02982641 12774921